CO2024003401A2 - Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias - Google Patents

Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias

Info

Publication number
CO2024003401A2
CO2024003401A2 CONC2024/0003401A CO2024003401A CO2024003401A2 CO 2024003401 A2 CO2024003401 A2 CO 2024003401A2 CO 2024003401 A CO2024003401 A CO 2024003401A CO 2024003401 A2 CO2024003401 A2 CO 2024003401A2
Authority
CO
Colombia
Prior art keywords
pyrazolo
treatment
autoimmune diseases
pyridine compounds
compounds
Prior art date
Application number
CONC2024/0003401A
Other languages
English (en)
Spanish (es)
Inventor
Ge Zou
Wei Zhu
Zhisen Zhang
Xiaoqing Wang
Dongdong Chen
Fabian Dey
Xin Hong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO2024003401A2 publication Critical patent/CO2024003401A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2024/0003401A 2021-09-24 2024-03-19 Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias CO2024003401A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021120406 2021-09-24
CN2022089033 2022-04-25
PCT/EP2022/076306 WO2023046806A1 (en) 2021-09-24 2022-09-22 Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
CO2024003401A2 true CO2024003401A2 (es) 2024-04-29

Family

ID=83688579

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0003401A CO2024003401A2 (es) 2021-09-24 2024-03-19 Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias

Country Status (16)

Country Link
US (1) US20240360126A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405051B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534567A (cg-RX-API-DMAC10.html)
KR (1) KR20240065092A (cg-RX-API-DMAC10.html)
CN (1) CN118076604A (cg-RX-API-DMAC10.html)
AR (1) AR127126A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022351495A1 (cg-RX-API-DMAC10.html)
CA (1) CA3228485A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000791A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024003401A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240134A (cg-RX-API-DMAC10.html)
IL (1) IL310443A (cg-RX-API-DMAC10.html)
MX (1) MX2024003444A (cg-RX-API-DMAC10.html)
PE (2) PE20250401A1 (cg-RX-API-DMAC10.html)
TW (1) TW202328129A (cg-RX-API-DMAC10.html)
WO (1) WO2023046806A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026515029A (ja) * 2023-04-28 2026-05-13 成都思倍博医▲薬▼科技有限公司 オキソピリド脂肪族環又は脂肪族複素環構造を含む化合物及びその医学的使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643967B2 (en) * 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
JP2021507889A (ja) * 2017-12-22 2021-02-25 ノバルティス アーゲー ピラゾロピペリジン誘導体の新規な使用
WO2019220390A1 (en) 2018-05-18 2019-11-21 Novartis Ag Crystalline forms of a tlr7/tlr8 inhibitor
CN112752755A (zh) * 2018-09-27 2021-05-04 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的杂环基化合物
JP2023533807A (ja) * 2020-07-14 2023-08-04 エフ. ホフマン-ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロイソキノリン又はヒドロナフチリジン化合物

Also Published As

Publication number Publication date
KR20240065092A (ko) 2024-05-14
EP4405051A1 (en) 2024-07-31
TW202328129A (zh) 2023-07-16
CL2024000791A1 (es) 2024-09-06
AU2022351495A1 (en) 2024-02-01
PE20240815A1 (es) 2024-04-18
CN118076604A (zh) 2024-05-24
JP2024534567A (ja) 2024-09-20
AR127126A1 (es) 2023-12-20
MX2024003444A (es) 2024-04-03
EP4405051B1 (en) 2026-07-15
PE20250401A1 (es) 2025-02-11
US20240360126A1 (en) 2024-10-31
WO2023046806A1 (en) 2023-03-30
CR20240134A (es) 2024-05-07
CA3228485A1 (en) 2023-03-30
IL310443A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
CO2025010435A2 (es) Compuestos tricíclicos para el tratamiento de cáncer
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
DOP2022000039A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
ECSP22050936A (es) Compuestos tric?clicos sustituidos
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
MX2021005754A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cancer.
AR133266A1 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
UY31727A (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica
CL2022000032A1 (es) Derivados de imidazo[4,5-c]piridina como agonistas de los receptores tipo toll
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
PY2132400A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
MX2020007443A (es) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de vasculitis y enfermedades inflamatorias.
AR115782A1 (es) DERIVADOS DE ESPIROCROMANO, UN MÉTODO PARA SU PREPARACIÓN, INTERMEDIARIOS PARA SU SÍNTESIS, COMPOSICIÓN Y COMBINACIÓN FARMACÉUTICA QUE LOS COMPRENDEN Y EL USO DE LOS MISMOS EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS AL RECEPTOR NICOTÍNICO DE ACETILCOLINA a7
CL2024000791A1 (es) Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias
CO2024000083A2 (es) Pirrolo[2,3-d]pirimidinas sustituidas, su preparación y su aplicación terapéutica
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR133167A1 (es) Macrociclos para el tratamiento de enfermedad autoinmunitaria
CL2024001524A1 (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
UY31593A1 (es) Derivados de 2-heteroaroil-imidazo[1,2-a]piridina, su preparacion y su aplicacion en terapéutica
AR131849A1 (es) Compuestos tricíclicos para el tratamiento de cáncer
AR133915A1 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
AR131945A1 (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno